免疫反应与炎症损伤在肝衰竭发病机制中的作用

王挺帅; 王娜; 张荣臻; 王明刚; 黄少东; 马玉珍; 吴聪; 毛德文

doi:10.3969/j.issn.1001-5256.2020.06.050

免疫反应与炎症损伤在肝衰竭发病机制中的作用

DOI: 10.3969/j.issn.1001-5256.2020.06.050

1. 湖南中医药大学研究生学院
2. 广西中医药大学第一附属医院肝病一区
3. 广西中医药大学研究生学院

基金项目:

国家自然科学基金(81774236,81560752)；广西科技攻关项目(2018GXNSFGA281002，桂科AD17129001，桂科AA17202036，桂科攻1598011-7,2017AB45166)；广西自然科学基金(2018JJA140362,2018JJA140500)；广西区中管局(GZZC16-17)；广西高校中青年教师基础能力提升项目(KY2016YB208)；

详细信息

中图分类号: R575.3
计量
- 文章访问数: 1347
- HTML全文浏览量: 56
- PDF下载量: 223
- 被引次数: 0
出版历程
- 出版日期: 2020-06-20

Role of immune response and inflammatory injury in the pathogenesis of liver failure

Research funding:

摘要

摘要:
肝衰竭是临床上常见的严重肝病症候群,该病救治难度大,病死率高,属于内科危急重症之一。肝细胞大量死亡、肝细胞死亡程度超过肝再生的能力被认为是肝衰竭发生发展的核心事件,直接损伤和免疫介导的炎症损伤是这一过程的两个主要因素。越来越多的证据表明,宿主免疫反应与炎症级联反应在肝衰竭发病机制中极为重要。综述了免疫调节(先天性和适应性)与炎症损伤(炎症诱导物、感受细胞、炎症介质)在肝衰竭过程中的作用机制,以及免疫反应/免疫细胞与炎症反应/炎症因子的交互作用,以期有助于了解肝衰竭的发病机制,为肝衰竭的诊疗、药物研发提供新思路。
- 肝功能衰竭 /
- 免疫调节 /
- 炎症
Abstract:
Liver failure is a syndrome of severe liver diseases commonly seen in clinical practice,and it has a high mortality rate and thus becomes one of the critical diseases in internal medicine. Massive hepatocyte death and the extent of hepatocyte death exceeding the liver's regenerative capacity are considered the core events in the development and progression of liver failure,and direct injury and immune-mediated inflammatory injury are the two main factors in this process. An increasing number of evidence has shown that host immune response and inflammatory cascade play an important role in the pathogenesis of liver failure. This article reviews the mechanism of action of immunoregulation( congenital and adaptive) and inflammatory injury( inflammation inducers,receptor cells,and inflammatory mediators) in the process of hepatic failure,as well as the interactions between immune response and immune cells and between inflammatory response and inflammatory factors,in order to help understand the pathogenesis of liver failure and provide new ideas for the diagnosis and treatment of liver failure and drug research and development.
- liver failure /
- immunomodulation /
- inflammatory

HTML全文

参考文献(59)

[1] Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,Chinese Medical Association; Severe Liver Disease and Artificial Liver Group,Chinese Society of Hepatology,Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol,2019,35(1):38-44.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝学组，中华医学会肝病学分会重型肝病与人工肝学组．肝衰竭诊治指南(2018年版)[J]．临床肝胆病杂志，2019,35(1):38-44.

[2] Chinese Society of Infectious Diseases,Chinese Medical Association; Chinese Society of Hepatology,Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol,2019,35(12):2648-2669.(in Chinese)中华医学会感染病学分会，中华医学会肝病学分会．慢性乙型肝炎防治指南(2019年版)[J]．临床肝胆病杂志，2019,35(12):2648-2669.

[3] THAWLEY V. Acute liver injury and failure[J]. Vet Clin North Am Small Anim Pract,2017,47(3):617-630.

[4] HERNAEZ R,SOLE,MOREAU R,et al. Acute-on-chronic liver failure:An update[J]. Gut,2017,66(3):541-553.

[5] WANG XJ,ZHANG XP,NING Q. Immune pathogenesis of liver failure[J]. J Clin Hepatol,2014,30(10):984-991.(in Chinese)王晓晶，张小平，宁琴．肝衰竭的免疫发病机制[J]．临床肝胆病杂志，2014,30(10):984-991.

[6] BLASCO-ALGORA S,MASEGOSA-ATAZ J,GUTIRREZGARCA ML,et al. Acute-on-chronic liver failure:Pathogenesis,prognostic factors and management[J]. World J Gastroenterol,2015,21(42):12125-12140.

[7] HENSLEY MK,DENG JC. Acute on chronic liver failure and immune dysfunction:A mimic of sepsis[J]. Semin Respir Crit Care Med,2018,39(5):588-597.

[8] WU JB,CHUANG HR,YANG LC,et al. A standardized aqueous extract of Anoectochilus formosanus ameliorated thioacetamide-induced liver fibrosis in mice:The role of Kupffer cells[J]. Biosci Biotechnol Biochem,2010,74(4):781-787.

[9] SU GL,KLEIN RD,AMINLARI A,et al. Kupffer cell activation by lipopolysaccharide in rats:Role for lipopolysaccharide binding protein and toll-like receptor 4[J]. Hepatology,2000,31(4):932-936.

[10] ELSEGOOD CL,CHAN CW,DEGLI-ESPOSTI MA,et al.Kupffer cell-monocyte communication is essential for initiating murine liver progenitor cell-mediated liver regeneration[J].Hepatology,2015,62(4):1272-1284.

[11] GUILLOT A,TACKE F. Liver macrophages:Old dogmas and new insights[J]. Hepatol Commun,2019,3(6):730-743.

[12] DOLGANIUC A,NORKINA O,KODYS K,et al. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection[J]. Gastroenterology,2007,133(5):1627-1636.

[13] WATT KD. The evolving role of the microbiome in liver failure and liver transplantation[J]. Liver Transpl,2016,22(S1):58-61.

[14] ARROYO V,MOREAU R,JALAN R,et al. Acute-on-chronic liver failure:A new syndrome that will re-classify cirrhosis[J]. J Hepatol,2015,62(1 Suppl):s131-s143.

[15] YU SY,ZHENG L,HAN F. Pathogenesis and treatment progress of antineutrophil cytoplasmic antibody-associated vasculitis[J]. Chin J Clin Pharmacol Ther,2018,23(2):235-240.(in Chinese)余淑媛，郑麟，韩飞．抗中性粒细胞胞质抗体相关性小血管炎的机制与治疗进展[J]．中国临床药理学与治疗学，2018,23(2):235-240.

[16] KOLACZKOWSKA E,KUBES P. Neutrophil recruitment and function in health and inflammation[J]. Nat Rev Immunol,2013,13(3):159-175.

[17] KEDARISETTY CK,ANAND L,BHARDWAJ A,et al. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis[J]. Gastroenterology,2015,148(7):1362-1370.

[18] WU DJ,JIN L,GAO YF,et al. Value of neutrophil-lymphocyte ratio in evaluating the short-time prognosis of patients with acute-on-chronic liver failure[J]. J Clin Hepatol,2018,34(9):1945-1949.(in Chinese)吴杜娟，金蕾，郜玉峰，等．中性粒细胞与淋巴细胞比值对慢加急性肝衰竭患者短期预后的评估价值[J]．临床肝胆病杂志，2018,34(9):1945-1949.

[19] CRISPE IN. The liver as a lymphoid organ[J]. Annu Rev Immunol,2009,27:147-163.

[20] SUNG PS,JANG JW. Natural killer cell dysfunction in hepatocellular carcinoma:Pathogenesis and clinical implications[J].Int J Mol Sci,2018,19(11):3648.

[21] WAN Z,XIE G,WU Y,et al. Cytokines elevated in patients with HBV-related acute-on-chronic liver failure promote NK cell mediated cytotoxicity through TRAIL[J]. Dig Liver Dis,2016,48(5):528-535.

[22] LIU F,DUAN X,WAN Z,et al. Lower number and decreased function of natural killer cells in hepatitis B virus related acuteon-chronic liver failure[J]. Clin Res Hepatol Gastroenterol,2016,40(5):605-613.

[23] ZOU Y,CHEN T,HAN M,et al. Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure[J].J Immunol,2010,184(1):466-475.

[24] CONSTANTINO J,GOMES C,FALCO A,et al. Dendritic cell-based immunotherapy:A basic review and recent advances[J]. Immunol Res,2017,65(4):798-810.

[25] LI BS,SUN Y,ZHANG LY,et al. Intrahepatic dendritic cells in patients with hepatitis B-related acute-on-chronic liver failure[J]. J Prac Hepatol,2012,15(5):400-403.(in Chinese)李保森，孙颖，张连业，等．慢加急性乙型肝炎肝衰竭患者肝组织树突状细胞特点研究[J]．实用肝脏病杂志，2012,15(5):400-403.

[26] ZHANG Y,CAI W,HUANG Q,et al. Mesenchymal stem cells alleviate bacteria-induced liver injury in mice by inducing regulatory dendritic cells[J]. Hepatology,2014,59(2):671-682.

[27] CRISPE IN. Liver antigen-presenting cells[J]. J Hepatol,2011,54(2):357-365.

[28] ZHOU X. Research progress of immune function of T lymphocyte[J]. Chin J Birth Health Heredity,2012,20(5):136-138.(in Chinese)周雄．T淋巴细胞免疫功能的研究进展[J]．中国优生与遗传杂志，2012,20(5):136-138.

[29] WANG DX,YU CH,YE YJ,et al. Research progress of T lymphocyte[J]. J Fourth Milit Med Univ,2009,30(24):3193-3195.(in Chinese)汪道鑫，虞春华，叶颖俊，等．T淋巴细胞的研究进展[J]．第四军医大学学报，2009,30(24):3193-3195.

[30] GAO MD,QIN L,SUN JP,et al. Expression and significance of T-cell immunoglobulin and mucin domain-containing molecule 3 in peripheral blood CD3+CD56+natural killer T cells in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. J Clin Hepatol,2019,35(9):2006-2010.(in Chinese)高梦丹，覃岭，孙坚萍，等．HBV相关慢加急性肝衰竭患者外周血CD3+CD56+自然杀伤T淋巴细胞中TIM-3的表达及意义[J]．临床肝胆病杂志，2019,35(9):2006-2010.

[31] WEI HX,CHUANG YH,LI B,et al. CD4+CD25+Foxp3+regulatory T cells protect against T cell-mediated fulminant hepatitis in a TGF-beta-dependent manner in mice[J]. J Immunol,2008,181(10):7221-7229.

[32] STOOP JN,van der MOLEN RG,BAAN CC,et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection[J]. Hepatology,2005,41(4):771-778.

[33] LIU GL,ZHOU XL,TAO P. The role of Th17/Treg cell balance in the clinical outcome of hepatitis B virus-associated acuteon-chronic liver failure[J]. Immunol J,2014,30(7):623-627,635.(in Chinese)刘光亮，周小兰，陶鹏．Th17/Treg细胞亚群数量变化在HBV相关ACLF临床转归中的作用[J]．免疫学杂志，2014,30(7):623-627,635.

[34] ZHANG H,HUANG LX,CHEN ZX,et al. Effect of CD4+CD25+Foxp3+regulatory T cells on acute-on-chronic liver failure caused by hepatitis B infection[J]. J Southeast Univ(Med Sci Edi),2011,30(2):315-318.(in Chinese)张慧，黄丽霞，陈朝霞，等．CD4+CD25+Foxp3+Treg细胞在HBV感染所致慢加急性肝衰竭中作用[J]．东南大学学报(医学版)，2011,30(2):315-318.

[35] CHEN YP,XU LM. Diagnosis and management of patients with hepatic failure:What's going on?[J]. J Prac Hepatol,2016,19(3):266-269.(in Chinese)陈永平，许烂漫．肝衰竭若干诊治要点探讨[J]．实用肝脏病杂志，2016,19(3):266-269.

[36] ZHAO L,QIU DK,MA X. Th17 cells:The emerging reciprocal partner of regulatory T cells in the liver[J]. J Dig Dis,2010,11(3):126-133.

[37] ZHAI S,ZHANG L,DANG S,et al. The ratio of Th-17 to Treg cells is associated with survival of patients with acute-on-chronic hepatitis B liver failure[J]. Viral Immunol,2011,24(4):303-310.

[38] YE Y,XIE X,YU J,et al. Involvement of Th17 and Th1 effector responses in patients with Hepatitis B[J]. J Clin Immunol,2010,30(4):546-555.

[39] QIAO J,WANG RQ,NAN YM. Research progress in prognostic biomarkers of liver failure[J]. Clin Med Chin,2020,36(1):80-83.(in Chinese)乔杰，王荣琦，南月敏．评估肝衰竭预后的生物学标志物研究进展[J]．中国综合临床，2020,36(1):80-83.

[40] CLRIA J,ARROYO V,MOREAU R. The acute-on-chronic liver failure syndrome,or when the innate immune system goes astray[J]. J Immunol,2016,197(10):3755-3761.

[41] HAO YQ. Pathogen related molecular model:A natural immune activator of great concern[J]. Int J Immunol,2003,26(5):243-246.(in Chinese)郝轶群．病原体相关分子模式———一种倍受关注的天然免疫活化剂[J]．国际免疫学杂志，2003,26(5):243-246.

[42] LAND WG,AGOSTINIS P,GASSER S,et al. Transplantation and damage-associated molecular patterns(DAMPs)[J].Am J Transplant,2016,16(12):3338-3361.

[43] KAWAI T,AKIRA S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity,2011,34(5):637-650.

[44] TAKEUCHI O,AKIRA S. Pattern recognition receptors and inflammation[J]. Cell,2010,140(6):805-820.

[45] AMARANTE-MENDES GP,ADJEMIAN S,BRANCO LM,et al. Pattern recognition receptors and the host cell death molecular machinery[J]. Front Immunol,2018,9:2379.

[46] CHEN QY,HAN DS. The functions of Toll-like receptors and their roles in liver diseases[J]. Chin J Cell Biol,2011,33(8):922-929.(in Chinese)陈巧媛，韩代书．Toll样受体在肝脏疾病中的功能[J]．中国细胞生物学学报，2011,33(8):922-929.

[47] FISHER JE,MCKENZIE TJ,LILLEGARD JB,et al. Role of Kupffer cells and toll-like receptor 4 in acetaminophen-induced acute liver failure[J]. J Surg Res,2013,180(1):147-155.

[48] SAD-SADIER N,OJCIUS DM. Alarmins,inflammasomes and immunity[J]. Biomed J,2012,35(6):437-449.

[49] KONO H,ROCK KL. How dying cells alert the immune system to danger[J]. Nat Rev Immunol,2008,8(4):279-289.

[50] GOU CY,LI L,LI XH. The role of damage related molecular model molecules in the pathogenesis of liver failure[J]. Beijing Med J,2015,37(9):885-887.(in Chinese)勾春燕，李丽，李秀惠．损伤相关分子模式分子在肝衰竭发病机制中的作用[J]．北京医学，2015,37(9):885-887.

[51] MAN SM,KARKI R,KANNEGANTI TD. Molecular mechanisms and functions of pyroptosis,inflammatory caspases and inflammasomes in infectious diseases[J]. Immunol Rev,2017,277(1):61-75.

[52] DU XX,SHI Y,YANG Y,et al. DAMP molecular IL-33 augments monocytic inflammatory storm in hepatitis B-precipitated acute-on-chronic liver failure[J]. Liver Int,2018,38(2):229-238.

[53] HEYMANN F,TACKE F. Immunology in the liver--from homeostasis to disease[J]. Nat Rev Gastroenterol Hepatol,2016,13(2):88-110.

[54] ANTOINE DJ,JENKINS RE,DEAR JW,et al. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity[J]. J Hepatol,2012,56(5):1070-1079.

[55] ARSHAD MI,PIQUET-PELLORCE C,SAMSON M. IL-33 and HMGB1 alarmins:Sensors of cellular death and their involvement in liver pathology[J]. Liver Int,2012,32(8):1200-1210.

[56] KALLIOLIAS GD,IVASHKIV LB. TNF biology,pathogenic mechanisms and emerging therapeutic strategies[J]. Nat Rev Rheumatol,2016,12(1):49-62.

[57] BARBIER L,FERHAT M,SALAME,et al. Interleukin-1 family cytokines:Keystones in liver inflammatory diseases[J]. Front Immunol,2019,10:2014.

[58] SANG JF,MA HC,SHI XL,et al. The beneficial effect of mesenchymal stem cells transplantation in combination with interleukin-1 receptor antagonist on post-hepatectomy liver failure[J]. Chin J Hepatobiliary Surg,2017,23(9):624-629.(in Chinese)桑剑锋，马虎成，施晓雷，等．间充质干细胞移植联合白介素-1受体拮抗剂治疗肝切除后肝脏功能衰竭[J]．中华肝胆外科杂志，2017,23(9):624-629.

[59] LIU YP,GU HH,XU J,et al. IL-32 expression in peripheral blood mononuclear cells of chronic hepatitis B virus-infected patients with PEG IFN-α-2a treated and its significance[J].Chin J Exp Clin Virol,2019,33(1):79-82.(in Chinese)刘永萍，顾慧华，徐晶，等．聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者外周血IL-32的表达水平及意义[J]．中华实验和临床病毒学杂志，2019,33(1):79-82.

施引文献

资源附件(0)

访问统计